Special Issue

MS-Based Drug Metabolism in Cancer Research

Message from the Guest Editor


I am contacting you as of the Special Issue "MS-Based Drug Metabolism in Cancer Research" to be published in the journal *Metabolites* (ISSN 2218-1989). I would be pleased if you agreed to contribute a short communication, research paper, or focused review to this Special Issue. I know that despite your numerous commitments, you have taken the time throughout your career to help new scientists learn and develop. As you are a leader in this field, I know our readers would be greatly interested in a contribution from you. I appreciate any help you could offer in this endeavor, and wish to thank you in advance for your consideration.

Guest Editor

Dr. Ala F. Nassar School of Medicine, Yale University, New Haven, CT, USA

Deadline for manuscript submissions

closed (30 September 2021)



an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 5.7 Indexed in PubMed



mdpi.com/si/68481

Metabolites
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 5.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2024).

